Here’s what surprises most people: acute myeloid leukemia (AML) doesn’t have stages 1 through 4 like breast cancer, lung cancer, or most solid tumors. If you searched for “stages of acute myeloid leukemia,” you’re probably expecting a neat staging chart — but AML works differently. Instead of a TNM staging system based on tumor size and spread, AML is classified by its genetic mutations, chromosomal changes, and how the leukemic cells look under a microscope. These classifications function as AML’s version of “stages” because they directly determine prognosis and treatment.
That said, AML does move through distinct treatment phases — untreated, in remission, refractory, or relapsed — and these phases act as practical “stages” that doctors use to guide therapy. Let’s break down both classification systems and what they actually mean for outcomes.
Why AML Doesn’t Use Traditional Staging
Solid tumors are staged by size, lymph node involvement, and whether they’ve metastasized to distant organs (the TNM system). AML can’t be staged this way because it’s a blood and bone marrow cancer — it’s essentially already “everywhere” in the bloodstream from the start.
Instead, AML prognosis depends almost entirely on the biology of the leukemia cells themselves. Two patients diagnosed on the same day with the same blast count can have wildly different outcomes based solely on which genetic mutations are driving their disease.
The Two Major AML Classification Systems
The FAB Classification (M0–M7)
The older French-American-British (FAB) system classifies AML into 8 subtypes based on how the leukemia cells look under a microscope and which cell lineage they come from. While largely replaced by the WHO system for treatment decisions, you’ll still see FAB subtypes referenced in medical records.
| FAB Subtype | Name | Key Feature |
|---|---|---|
| M0 | Minimally differentiated AML | Very immature blasts, no clear lineage markers |
| M1 | AML without maturation | Myeloblasts with minimal maturation |
| M2 | AML with maturation | Often associated with t(8;21); generally favorable |
| M3 | Acute promyelocytic leukemia (APL) | PML-RARA fusion; best prognosis (cure rate >90%) |
| M4 | Acute myelomonocytic leukemia | Both myeloid and monocytic differentiation |
| M5 | Acute monocytic leukemia | Monocytic blasts; can infiltrate gums and skin |
| M6 | Acute erythroid leukemia | Erythroid precursors predominate |
| M7 | Acute megakaryoblastic leukemia | Megakaryocytic blasts; associated with Down syndrome in children |
The WHO Classification (Current Standard)
The World Health Organization (WHO) classification, most recently updated in 2022, is what oncologists actually use today. It categorizes AML based on recurrent genetic abnormalities, differentiation lineage, and clinical history (such as whether the AML evolved from a prior blood disorder or was caused by prior chemotherapy).
This matters because specific genetic changes predict how well a patient will respond to treatment — far more accurately than cell appearance alone.
AML Risk Stratification: The Closest Thing to “Stages”
The European LeukemiaNet (ELN) 2022 risk stratification is the framework most hematologists use to estimate prognosis. It divides AML into three risk groups based on cytogenetics and molecular mutations. This is functionally the most important “staging” system in AML.
| Risk Group | Key Genetic Features | Approximate 5-Year Survival |
|---|---|---|
| Favorable | t(8;21), inv(16), mutated NPM1 without FLT3-ITD, CEBPA bZIP mutations | 60–70% |
| Intermediate | Normal cytogenetics, mutated NPM1 with FLT3-ITD, t(9;11) | 25–45% |
| Adverse | Complex karyotype (≥3 abnormalities), monosomal karyotype, TP53 mutation, RUNX1 mutation, ASXL1 mutation | 10–15% |
A patient with favorable-risk AML and a patient with adverse-risk AML have completely different treatment plans and expected outcomes. This risk group assignment drives the single biggest treatment decision in AML: whether to proceed to a bone marrow transplant in first remission.
Treatment Phases of AML (The Practical “Stages”)
While AML lacks formal staging, it does progress through well-defined treatment phases that clinicians track closely:
- Untreated AML: Newly diagnosed disease. Bone marrow typically contains ≥20% blasts (the WHO diagnostic threshold). Without treatment, survival is measured in weeks to months.
- Remission induction: The first round of intensive chemotherapy — usually “7+3” (7 days of cytarabine + 3 days of an anthracycline like daunorubicin). Complete remission (CR) is achieved in roughly 60–80% of patients under 60 and 40–60% of older adults.
- Post-remission/consolidation: Chemotherapy or stem cell transplant to eliminate residual leukemia cells. Without consolidation, relapse is almost guaranteed.
- Refractory AML: Leukemia that doesn’t respond to initial induction chemotherapy. This occurs in about 20–40% of cases and carries a poor prognosis.
- Relapsed AML: Leukemia that returns after achieving remission. Median time to relapse is typically 12–18 months. Outcomes depend heavily on how long the first remission lasted.
Key Mutations That Shape Prognosis
Modern AML management depends on molecular profiling. At diagnosis, your oncologist should test for a panel of mutations that directly impact both prognosis and treatment options:
- FLT3-ITD: Present in ~25% of AML cases. Associated with higher relapse rates but now targetable with midostaurin or gilteritinib.
- NPM1: Mutated in ~30% of cases. Generally favorable when FLT3-ITD is absent.
- TP53: Mutated in ~10% of cases. One of the worst prognostic markers in all of AML, with median survival often under 6 months.
- IDH1/IDH2: Targetable with ivosidenib and enasidenib, respectively — oral medications that can induce remission even in older or unfit patients.
- DNMT3A: Common mutation (~20% of cases) associated with intermediate prognosis.
When to See a Doctor
AML often presents abruptly. Seek urgent medical evaluation if you experience persistent unexplained fatigue, frequent infections, easy bruising or bleeding, or bone pain — especially if symptoms escalate over days to weeks rather than months. A simple complete blood count (CBC) can reveal the hallmark findings: low hemoglobin, low platelets, and elevated or abnormal white blood cells with circulating blasts.
If you’ve already been diagnosed with AML, ask your hematologist specifically about your ELN risk category and which molecular mutations were found. These two pieces of information matter more than almost anything else for your treatment plan and expected outcome.
Frequently Asked Questions
Is there a stage 4 AML?
No. AML is not staged using the stage 1–4 system that applies to solid tumors. Instead, AML is classified by genetic and chromosomal features into favorable, intermediate, and adverse risk groups. These risk groups serve the same prognostic purpose as traditional staging.
What is the survival rate for AML?
Overall 5-year survival for AML is approximately 30% across all age groups, according to SEER data. However, this varies enormously: favorable-risk AML in younger patients can exceed 70% five-year survival, while adverse-risk AML in older adults may have survival measured in months. Age, fitness, and genetic subtype all matter significantly.
How fast does AML progress?
AML is aggressive. Without treatment, it can be fatal within weeks to a few months. The leukemic blast count can double rapidly, and bone marrow failure — causing severe anemia, bleeding, and infection — develops quickly. This is why AML treatment typically starts within days of diagnosis, not weeks.
Can AML be cured?
Yes, AML is potentially curable, particularly in younger patients with favorable-risk disease. Promyelocytic Leukemia: From Definition to…”>Acute promyelocytic leukemia (APL, the M3 subtype) has cure rates exceeding 90% with all-trans retinoic acid (ATRA) and arsenic trioxide. For other subtypes, allogeneic stem cell transplant offers the best chance of long-term cure in intermediate and adverse-risk groups.
What tests determine my AML risk group?
Your hematologist will order cytogenetic analysis (karyotyping and FISH) to look at chromosomal changes, along with a molecular mutation panel that tests for FLT3, NPM1, CEBPA, TP53, IDH1/2, and other relevant genes. Flow cytometry confirms the diagnosis, and these combined results determine your ELN risk stratification. Results typically take 5–14 days, though some rapid PCR tests return within 48 hours.
